A "green" strategy to construct non-covalent, stable and bioactive coatings on porous MOF nanoparticles

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Agostoni, V ^a   Horcajada, P ^b   Noiray, M ^a   Malanga, M ^c   Aykac A ^d   Jicsinszky, L ^c   Vargas Berenguel, A ^d   Semiramoth, N ^a   Daoud Mahammed, S ^a   Nicolas, V ^e   Martineau, C ^b   Taulelle, F ^b   Vigneron, J ^b   Etcheberry, A ^b   Serre, C ^b   Gref, R ^a,e  

^a UNIV PARIS SUD   (France)

^b UNIVERSITÉ DE VERSAILLES SAINT QUENTIN EN YVELINES   (France)

^c CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

^d UNIVERSITY OF ALMERÍA   (Spain)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBLE COATED MATERIAL; NANOPARTICLE;

ANIMAL; CELL LINE; CHEMISTRY; MATERIALS TESTING; MOUSE; POROSITY;

ANIMALS; CELL LINE; COATED MATERIALS, BIOCOMPATIBLE; MATERIALS TESTING; MICE; NANOPARTICLES; POROSITY;

EID: 84923076506     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07925     Document Type: Article

References (46)

1. Clearfield, A. Metal-phosphonate chemistry. Prog. Inorg. Chem. 47, 371-510 (1998).
2. Eddaoudi, M. et al. Modular chemistry: secondary building units as a basis for the design of highly porous and robust metal2organic carboxylate frameworks. Acc. Chem. Res. 34, 319-330 (2001).
3. 3]n. Science 283, 1148-1150 (1999).
4. Férey, G. et al. A Chromium Terephthalate-Based Solid with Unusually Large Pore Volumes and Surface Area. Science 309, 2040-2042 (2005).
5. Kitagawa, S., Kitaura, R. & Noro, S. I. Functional Porous Coordination Polymers. Angew. Chem. Int. Ed. 43, 2334-2375 (2004).
6. Maspoch, D., Ruiz-Molina, D. & Veciana, J. Old materials with new tricks: multifunctional open-framework materials. Chem. Soc. Rev. 36, 770-818 (2007).
7. Hoskins, B. F. & Robson, R. Infinite polymeric frameworks consisting of three dimensionally linked rod-like segments. J. Am. Chem. Soc. 111, 5962-5964 (1989).
8. Serre, C. et al. Role of Solvent-Host Interactions That Lead to Very Large Swelling of Hybrid Frameworks. Science 315, 1828-1831 (2007).
9. Yaghi, O.M.etal. Hydrogen Storage inMicroporous Metal-OrganicFrameworks. Nature 423, 705-714 (2003)
10. Perry, J. J., Perman, J. A. & Zaworothko, M. J. Design and synthesis of metal-organic frameworks using metal-organic polyhedra as supermolecular building blocks. Chem. Soc. Rev. 38, 1400-1417 (2009).
11. Zhou, H.-C., Long, J. R. & Yaghi, O. M. Introduction to Metal2Organic Frameworks. Chem. Rev. 112, 673-674 (2012).
12. Dhakshinamoorthy, A. & Garcia, H. Catalysis by metal nanoparticles embedded on metal-organic frameworks. Chem. Soc. Rev. 41, 5262-5284 (2012).
13. Horcajada, P. et al. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 9, 172-178 (2010).
14. Horcajada, P. et al. Metal-organic frameworks in biomedicine. Chem. Rev. 112, 1232-1268 (2012).
15. Horcajada, P. et al. Metal-organic frameworks as efficient materials for drug delivery. Angew. Chem. Int. Ed. 45, 5974-5978 (2006).
16. Huxford, R. C., Della Rocca, J. & Lin, W. Metal-organic frameworks as potential drug carriers. Curr. Opin. Chem. Biol. 14, 262-268 (2010).
17. Férey, G., Mellot-Draznieks, C., Serre, C. & Millange, F. Crystallized frameworks with giant pores: are there limits to the possible? Acc. Chem. Res. 38, 217-225 (2005).
18. Yaghi, O. Special issue on Reticular Chemistry: Design, Synthesis, Properties and Applications of Metal-Organic Polyhedra and Frameworks. J. Solid State Chem. 178, 2409-2574 (2005).
19. Horcajada, P. et al. How linker's modification controls swelling properties of highly flexible iron(III) dicarboxylates MIL-88. J. Am. Chem. Soc. 133, 17839-17847 (2011).
20. Imaz, I. et al. Metal-biomolecule frameworks (MBioFs). Chem. Commun. 47, 7287-7302 (2011).
21. Cohen, S. M. Postsynthetic methods for the functionalization of metal-organic frameworks. Chem. Rev. 112, 970-1000 (2011).
22. Ferey, G. & Serre, C. Large breathing effects in three-dimensional porous hybrid matter: facts, analyses, rules and consequences. Chem. Soc. Rev. 38, 1380-1399 (2009).
23. Baati, T. et al. In depth analysis of the in vivo toxicity of nanoparticles of porous iron(III) metal-organic frameworks. Chem. Sci. 4, 1597-1607 (2013).
24. Agostoni, V. et al. Towards an Improved anti-HIV Activity of NRTI via Metal-Organic Frameworks Nanoparticles. Adv. Healthcare Mater. 2, 1630-1637 (2013).
25. Chalati, T. et al. Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation. Nanomedicine 6, 1683-1695 (2011).
26. Cunha, D.et al. Rationale ofDrug Encapsulation and Release from Biocompatible Porous Metal-Organic Frameworks. Chem. Mater. 25, 2767-2776 (2013).
27. Horcajada, P. et al. Flexible porous metal-organic frameworks for a controlled drug delivery. J. Am. Chem. Soc. 130, 6774-6780 (2008).
28. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994).
29. Guerrero-Martinez, A., Pérez-Juste, J. & Liz-Marzan, L. M. Recent progress on silica coating of nanoparticles and related nanomaterials. Adv. Mater. 22, 1182-95 (2010).
30. Lim, M. H. & Stein, A. Comparative studies of grafting and direct syntheses of inorganic-organic hybrid mesoporous materials. Chem. Mater. 11, 3285-3295 (1999).
31. Rieter, W. J., Pott, K. M., Taylor, K. M. L. & Lin, W. Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery. J. Am. Chem. Soc. 130, 11584-11585 (2008).
32. Huxford, R. C., de Kraft, K. E., Boyle, W. S., Liu, D. & Lin, W. Lipid-coated nanoscale coordination polymers for targeted delivery of antifolates to cancer cells. Chem. Sci. 3, 198-204 (2012).
33. Rowe, M. D. et al. Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. Langmuir 25, 9487-9499 (2009).
34. Rowe, M. D., Thamm, D. H., Kraft, S. L. & Boyes, S. G. Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromol. 10, 983-993 (2009).
35. Taylor, K. M. L., Rieter, W. J. & Lin, W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc. 130, 14358-14359 (2008).
36. Taylor-Pashow, K. M. L., Rocca, J. D., Xie, Z., Tran, S. & Lin, W. Postsynthetic Modifications of Iron-Carboxylate Nanoscale Metal2Organic Frameworks for Imaging and Drug Delivery. J. Am. Chem. Soc. 131, 14261-14263 (2009).
37. Horcajada, P. et al. Synthesis and catalytic properties of MIL-100(Fe), an iron(III) carboxylate with large pores. Chem. Commun. 27, 2820-2822 (2007).
38. Loftsson, T. & Duchêne, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329, 1-11 (2007).
39. Davis, M. E. & Brewster, M. E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3, 1023-1035 (2004).
40. Gref, R. & Duchene, D. Cyclodextrins as «smart» components of polymer nanoparticles. J. Drug Del. Sci. Tech. 22, 209-272 (2012).
41. Allen, C. et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep. 22, 225-250 (2002).
42. Steels, B. M., Koska, J. & Haynes, C. A. J. Analysis of brush-particle interactions using self-consistent-field theory. Chromatogr. B 743, 41-56 (2000).
43. Liu, Y., Yu, Z.-L., Zhang, Y.-M., Guo, D.-S. & Liu, Y.-P. Supramolecular Architectures of b-Cyclodextrin-Modified Chitosan and Pyrene Derivatives Mediatedby Carbon Nanotubes and Their DNA Condensation.J. Am. Chem. Soc. 130, 10431-10439 (2008).
44. Anand, R. et al. Citric acid-Y-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery. Photochem. Photobiol. Sci. 12, 1841-1854 (2013).
45. Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659-668 (2009).
46. Gary-Bobo, M. et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. Int. J. Pharm. 432, 99-104 (2012).